RPL17 and melanoma: Although there are reported differences between tumor subtypes, the concordance of PD-1/PD-L1 expression and TMB-H is reportedly 32% in melanoma, 12% in non-small cell lung cancer (NSCLC), 2.4% in endometrial cancer, 2.2% in esophageal cancer, and 1.2% of colorectal cancer.